World Journal of
Pharmaceutical and Life Sciences

An International Peer Reviewed Journal for Pharmaceutical and Life Sciences
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
World Journal of Pharmaceutical and Life Sciences (WJPLS) has indexed with various reputed international bodies like : Google Scholar, Index Copernicus, Indian Science Publications, SOCOLAR, China, Cosmos Impact Factor, Research Bible, Fuchu, Tokyo. JAPAN, Scientific Indexing Services (SIS), Jour Informatics (Under Process), UDLedge Science Citation Index, Global Impact Factor (In Process), International Impact Factor Services, International Scientific Indexing, UAE, International Society for Research Activity (ISRA) Journal Impact Factor (JIF), Science Library Index, Dubai, United Arab Emirates, International Innovative Journal Impact Factor (IIJIF), Scientific Journal Impact Factor (SJIF), Eurasian Scientific Journal Index (ESJI), Indian citation Index (ICI), IFSIJ Measure of Journal Quality, International Scientific Indexing, UAE (ISI), Web of Science Group (Under Process), Directory of Research Journals Indexing, 



*Dr. Sheetal Gupta, [BAMS MD SWASTHVRITA] and Dr. Rahul Sharma [Bams]


Background: Chandraprabha vati is a classical Ayurvedic formulation, markedly used for mitigation of prameha, which corelates in many ways with obesity, metabolic syndrome and diabetes mellitus. Objective: The present study was aimed to investigate effect of Chandraprabha vati in experimentally induced hyperglycemia and lipid profile alterations. Materials and Methods: Antidiabetic effect of Chandraprabha vati was studied in fiftyfive Wistar rat. Graded doses of Chandraprabha vati (50,100 and 200mg/kg, orally) were administered orally for 7 days to normal and alloxan-hyperglycemic rats (65 mg/kg, intravenously), and to glucose loaded normal rats for oral glucose tolerance test (OGTT). Fasting plasma glucose levels were assessed on different time intervals along with plasma cholesterol and triglycerides. Metformin (500 mg/kg orally) was used as standard drug. Results: Chandraprabha vati did not cause any significant reduction in plasma glucose levels of normal rats (p > 0.05) but normalized the impaired glucose tolerance at 60 and 120 min (p<0.05-p<0.001) in OGTT when compared to vehicle control. In alloxan-hyperglycemic rats, administration of chandraprabhavati vati (200 mg/kg) significantly reduced plasma glucose at 3 h, 12 h, 3rd day and 7th day (p<0.01-p<0.001) along with reduction in cholesterol and triglycerides levels (p<0.01-p<0.001) when compared to diabetic control group. The effects were comparable with metformin. Conclusions: Chandraprabha vati exhibited anti-hyperglycemic effect and attenuated alterations in lipid profile. The results support the use of chandraprabha vati for correction of Prameha in clinical practice.

[Full Text Article]


World Journal of Pharmaceutical and life sciences Will give best paper award in every issue in the from of money along with certificate to promote research .

Best Article of current issue

Download Article : Click here